181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts). (December 2022) - Gumus, M.; Sukalinskaya, A.; Andric, Z.G.; Cheshuk, V.; Ciuleanu, T-E.; Sezgin Goksu, S.; Cil, T.; Cicin, I.; Bulat, I.V.; Ostapenko, Y.V.; Penkov, K.D.; Hart, C.; et al.